Record sales quarter closes an eventful year
- Net revenue for the quarter increased by 27 per cent to EUR 104.9m (82.5) with organic growth of 15 per cent
- Adjusted EBITA increased 9 per cent to EUR 24.6m (22.6), corresponding to a margin of 23.4 per cent (27.5)
- Operating profit (EBIT) of EUR 12.5m (2.7)
- Profit of EUR 12.5m (-6.3) and earnings per share before and after dilution EUR 0.02 (-0.01)
- Cash flow from operating activities of EUR 24.4m (17.2)
"Vimian closed an eventful year with all-time high revenues in the fourth quarter, reaching EUR 104.9 million. We continued to report strong organic growth of 15 per cent, ahead of the overall animal health market", says Patrik Eriksson, CEO Vimian Group.
Revenue for the full year increased by 13 per cent to EUR 374.8m (331.7) with organic growth of 9 per cent. Adjusted EBITA increased by 9 per cent to EUR 95.2m (87.3) corresponding to a margin of 25.4 per cent (26.3). Cash flow from operations reached EUR 58.1m (-28.6).
"In 2024, we have delivered strong results and achieved several key milestones including new financial targets, a successful rights issue and our entrance into the fast-growing niche veterinary dental. We are well-positioned to continue drive strong profitable growth by addressing significant white space in our market niches and complete value-creative acquisitions", concludes Patrik Eriksson.
A telephone and webcast will be held for investors, analysts, and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.
To attend the telephone conference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
https://conference.inderes.com/teleconference/?id=5006112
To attend the webcast:
Link: https://vimian-group.events.inderes.com/q4-report-2024
Related presentation materials will be available on Vimian's website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.
For further information, please contact:
Maria Dahllöf Tullberg
Head of IR, Communications & Sustainability
maria.tullberg@vimian.com
+46 736 26 88 86
About Vimian
Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Veterinary Services and Diagnostics. At Vimian, we believe that every animal deserves the best available care. We bring pioneering and entrepreneurial businesses together to make the market's most innovative offerings accessible to more animal health professionals and pet owners. Headquartered in Stockholm, Sweden, Vimian reaches over 17,000 veterinary clinics and laboratories, sells to over 80 markets, has 1,200 employees and annual revenues of approximately EUR 375 million. For more information, please visit: www.vimian.com. FNCA Sweden AB is appointed the Company's Certified Adviser.
This information is information that Vimian Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-02-13 07:45 CET.
